S&P 500 7,511 -0.43% Nasdaq 25,842 -1.02% Dow Jones 52,340 -0.32% FTSE 100 10,586 +0.54% DAX 25,011 -0.54% Nikkei 225 66,232 -2.23% Hang Seng 25,132 +3.25% WTI Crude 84.25 +6.71% Gold 4,080 +2.37% US 10-Year Treasury Yield 4.628 +1.83% S&P 500 7,511 -0.43% Nasdaq 25,842 -1.02% Dow Jones 52,340 -0.32% FTSE 100 10,586 +0.54% DAX 25,011 -0.54% Nikkei 225 66,232 -2.23% Hang Seng 25,132 +3.25% WTI Crude 84.25 +6.71% Gold 4,080 +2.37% US 10-Year Treasury Yield 4.628 +1.83%

LATEST

Police recover 285 vandalised NNPC pipelines in Adamawa, arrest seven suspects●OpenAI, Anthropic boost lobbying as legacy tech and defense spending slips●IRS chief Frank Bisignano laughs off JPMorgan spying allegations●Unilever Nigeria Sustains Revenue and Profit Growth, delivers ₦119.9bn Revenue & Declares Interim Dividend●Microsoft has 3 secret weapons that could drive its stock 50% higher, analyst says●FirstBank backs Theatre @ Eko’s ‘Prideland’ musical to drive creative industry growth●U.S. Senator: Clarity Act is ‘Almost There,’ Treasury Secretary Puts It at the ‘1-Yard Line’●XRP Breaks Out on Clarity Act Hopes. The Charts Are Still Cautious●Police recover 285 vandalised NNPC pipelines in Adamawa, arrest seven suspects●OpenAI, Anthropic boost lobbying as legacy tech and defense spending slips●IRS chief Frank Bisignano laughs off JPMorgan spying allegations●Unilever Nigeria Sustains Revenue and Profit Growth, delivers ₦119.9bn Revenue & Declares Interim Dividend●Microsoft has 3 secret weapons that could drive its stock 50% higher, analyst says●FirstBank backs Theatre @ Eko’s ‘Prideland’ musical to drive creative industry growth●U.S. Senator: Clarity Act is ‘Almost There,’ Treasury Secretary Puts It at the ‘1-Yard Line’●XRP Breaks Out on Clarity Act Hopes. The Charts Are Still Cautious●

Wealth

Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications

MarketWatch.com - Top Stories · 4h ago · 🇺🇸 United States

Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications

The Danish company Novo says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs.

Read the full story at MarketWatch.com - Top Stories →

More Wealth

Microsoft has 3 secret weapons that could drive its stock 50% higher, analyst says

MarketWatch.com - Top Stories · 27m ago

These signs suggest investors should give the software sector a second chance

MarketWatch.com - Top Stories · 42m ago

Why Paramount could win if it loses the Warner Bros. Discovery deal

MarketWatch.com - Top Stories · 1h ago

Tesla earnings are on deck, and investors will be looking to settle this major debate

MarketWatch.com - Top Stories · 2h ago